# Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

> **NCT06054932** · PHASE1 · UNKNOWN · sponsor: **Beijing Likang Life Science and Tech Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LK101 injection
- **DRUG:** LK101 injection

## Key facts

- **NCT ID:** NCT06054932
- **Lead sponsor:** Beijing Likang Life Science and Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-05
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06054932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06054932, "Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06054932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*